My letter to Eli Lilly (makers of Solanezumab)

Dear Sirs
Today the media was full of reports about Solanezumab, your proposed drug to prevent or curtail the progression of Alzheimers Disease through interaction with amyloid plaques. I am curious to know what data you based this claim on as in January 2014 the New England Journal of Medicine reported that, in Phase 3 trials,”Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability.”
I am confused that it is now being touted as a wonder drug. I would be grateful if you could provide an explanation.
Yours faithfully

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s